Study of biotransformation of new selective carbonic anhydrase II inhibitor 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide
-
Published:2023-11-20
Issue:3
Volume:11
Page:240-254
-
ISSN:2413-2241
-
Container-title:Pharmacy & Pharmacology
-
language:
-
Short-container-title:Farm. farmakol. (Pâtigorsk)
Author:
Khokhlov A. L.1ORCID, Yaichkov I. I.2ORCID, Shetnev A. A.1ORCID, Ivanovskiy S. A.1ORCID, Korsakov M. K.1ORCID, Gasilina O. A.1ORCID, Volkhin N. N.1ORCID, Petukhov S. S.2ORCID
Affiliation:
1. Yaroslavl State Medical University 2. 1.Yaroslavl State Pedagogical University named after K.D. Ushinsky.
2.Yaroslavl State Medical University
Abstract
The aim of the study was to determine biotransformation products of a new selective carbonic anhydrase II inhibitor – 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide.Materials and methods. The study was conducted on 3 Wistar rats and 3 rabbits of the Soviet Chinchilla breed. The suspension of the drug was administered intraperitoneally to rats at a dosage of 20 mg/kg, to rabbits - at a dosage of 1.6 mg/kg. The animal blood samples were collected before the administration and 1, 2, 4, 24 h after. Urine sampling was also performed in the rats before the administration and in the intervals of 0–4, 4–8, 8–24 h after. The identification of metabolites in blood, urine and plasma was carried out using HPLC-MS/MS. Poroshell 120 C 18 column (50×3.0 mm, 2.7 µm) with a Zorbax Eclipse Plus C18 pre-column (12.5×2.1 mm, 5.0 µm) was used for the chromatographic separation. The assumed metabolites were synthesized, their structure was confirmed by the NMR spectroscopy method and a high-resolution mass spectrometry. The obtained substances were compared with the substances identified in biological fluids by retention time, the main MRM-transitions and mass spectra.Results. The N-hydroxymetabolite was revealed in the analyses of plasma, blood and urine samples which had been formed by the addition of an oxygen atom to the drug molecule. Chromatographic peaks of this compound were identified at the MRM-transitions of 255→159, 255→117, 255→89 m/z at the 7.2nd min of the analysis. The N-oxide of 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide and N-hydroxy-4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide were synthesized; potentially, they could have been obtained during the biotransformation. During the confirmatory HPLC-MS/MS tests based on the coincidence of the retention times, the main MRM transitions and mass spectra, the ratio of the peak areas at the identified metabolite it was established that an N-hydroxy derivative. Chromatographic peaks of the N-oxide detected in the analysis of the model mixtures of the standard substance at the MRM-transitions of 255→175, 255→133, 255→89 m/z at the retention time of 5.43 min, were absent in the animal samples.Conclusion. The studied drug is metabolized to form a single metabolite of N-hydroxy-4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide. This compound was found in freshly collected samples of biological fluids of both animal species. The structure of the metabolite was confirmed by the HPLC-MS/MS-method by comparison with the synthesized standard substance.
Publisher
Volgograd State Medical University
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Pharmacy,Pharmacology (nursing)
Reference29 articles.
1. Efimova JA, Shetnev AA, Gasilina OA. Korsakov MK. The efficient route for the synthesis of 4-(2-methyl-1,3-oxazole-5- yl)-benzenesulfonamide – a promising new generation antiglaucoma agent. Butlerov Communications. 2022;72(12):15–20. DOI: 10.37952/ROI-jbc-01/22-72-12-15. Russian 2. Ivanovsky SA, Veselova VN, Shetnev AA, Korsakov MK. Development and validation of a methodology for the quantitative determination of Oxazopt API. Butlerov Communications. 2022;72(12):139–46. DOI: 10.37952/ROI-jbc-01/22-72-12-139. Russian 3. Ferraroni M, Luccarini L, Masini E, Korsakov M, Scozzafava A, Supuran CT, Krasavin M. 1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads. Bioorg Med Chem. 2017;25(17):4560-5. DOI: 10.1016/j.bmc.2017.06.054 4. Krasavin M, Korsakov M, Dorogov M, Tuccinardi T, Dedeoglu N, Supuran CT. Probing the ‘bipolar’ nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms. Eur J Med Chem. 2015 Aug 28;101:334-47. DOI: 10.1016/j.ejmech.2015.06.022 5. Aladysheva ZhI, Belyaev VV, Beregovykh VV, Brkich GE, Greibo SV, Demina NB, Dzhurko YuA, Ivanovsky SA, Nikolenko NS, Komissarova VA, Korsakov MK, Lavrentieva LI, Meshkovsky AP, Miroshnikov AE, Onegin SV, Parfenov AA, Pozdnyakov NO, Poroikov VV, Pyatigorskaya NV, Pyatigorsky AM, Rakov AA, Sidorov AV, Spitsky OR, Trubnikov AA, Khokhlov AA, Khokhlov AL, Chikina IV, Shabalina MM, Shabrov VN, Shitov LN., Yaichkov II. Industrial Pharmacy: The Way to Create a Product: Monograph. Khokhlov AL, Pyatigorskaya NV, editors. Moscow: The Russian Scientific Academy; 2019, 394 p. Russian
|
|